Free tool
FAERS Monitor: Tavneos
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214487 or its brand name (Tavneos, Avacopan). Reports on generic versions are filed under their own applications.
Reports
6,762
Serious
5,036
74% of reports
Hospitalization
3,168
Death reported
691
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hospitalisation1,026
- death414
- off label use373
- therapy interrupted354
- diarrhoea272
- fatigue270
- nausea249
- pneumonia245
- headache183
- covid-19176
- product dose omission issue158
- dialysis145
- drug ineffective145
- infection145
- dyspnoea142
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 8 |
| 2022 | 462 |
| 2023 | 1,671 |
| 2024 | 1,242 |
| 2025 | 1,727 |
| 2026 | 1,652 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,397 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dialysisSignal | 145 | 32.1 | 27.3 | 4,297 |
| hospitalisationSignal | 1,026 | 20.9 | 19.8 | 19,436 |
| therapy interruptedSignal | 354 | 15.5 | 14.0 | 4,773 |
| covid-19Signal | 176 | 3.1 | 2.7 | 254 |
| infectionSignal | 145 | 3.1 | 2.7 | 208 |
| pneumoniaSignal | 245 | 2.4 | 2.1 | 192 |
| product dose omission issue | 158 | 1.7 | 1.4 | 43 |
| death | 414 | 1.5 | 1.4 | 70 |
| off label use | 373 | 1.3 | 1.2 | 31 |
| diarrhoea | 272 | 1.3 | 1.2 | 20 |
| fatigue | 270 | 1.1 | 1.0 | 2 |
| nausea | 249 | 1.0 | 0.9 | 0 |
| headache | 183 | 0.9 | 0.8 | 2 |
| dyspnoea | 142 | 0.8 | 0.7 | 9 |
| drug ineffective | 145 | 0.3 | 0.3 | 195 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.